COSM (Cosmos Health) Retained Earnings : $-104.48 Mil (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cosmos Health Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cosmos Health's retained earnings for the quarter that ended in Sep. 2024 was $-104.48 Mil.

Cosmos Health's quarterly retained earnings declined from Mar. 2024 ($-93.51 Mil) to Jun. 2024 ($-96.10 Mil) and declined from Jun. 2024 ($-96.10 Mil) to Sep. 2024 ($-104.48 Mil).

Cosmos Health's annual retained earnings declined from Dec. 2021 ($-34.35 Mil) to Dec. 2022 ($-66.23 Mil) and declined from Dec. 2022 ($-66.23 Mil) to Dec. 2023 ($-91.64 Mil).

Cosmos Health Retained Earnings Historical Data

The historical data trend for Cosmos Health's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmos Health Retained Earnings Chart

Cosmos Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-19.57

-18.75

-34.35

-66.23

-91.64

Cosmos Health Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															-71.04	-91.64	-93.51	-96.10	-104.48

Cosmos Health Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Cosmos Health (NAS:COSM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Cosmos Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cosmos Health Inc (NAS:COSM) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

V67A:Germany

Address

5 Agiou Georgiou Street, Thessaloniki, Thessaloniki, GRC, 55438

Website

https://www.cosmoshealthinc.com

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

Executives

Grigorios Siokas	10 percent owner	5 AG. GEORGIOU STR., PILEA, THESSALONIKI J3 TK57001
Suhel Bhutawala	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Nikolaos Bardakis	officer: Chief Operating Officer	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Manfred Ziegler	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Anastasios Aslidis	director	11 CANTERBURY LANE, WATCHUNG NJ 07069
Pavlos Ignatiades	officer: Chief Operating Officer	KALAPATHAKI 5, PANORAMA, THESSALONIKI J3 55236
Georgios Terzis	officer: Chief Financial Officer	2 MELITOS STR., NEA SMIRNI, ATTICA J3 17121
Peter Goldstein	director	151 NORTH NOB HILL ROAD SUITE 321, FORT LAUDERDALE FL 33324
John James Hoidas	director	9301 S. HARLEM AVENUE, OAK LAWN, CHICAGO IL 60453
Dimitrios Goulielmos	director, 10 percent owner, officer: CEO	141 WEST JACKSON BLVD, SUITE 4236, CHICAGO IL 60604
Panagiotis Tolis	director, officer: Secretary	PERICLEOUS 50 STREET, ATHENS J3 15232
Panagiotis Drakopoulos	director, 10 percent owner, officer: CEO	200 SOUTH WACKER DRIVE, SUITE 300, CHICAGO IL 60606
Vasileios Mavrogiannis	director, 10 percent owner, officer: CFO	TERTSETI 23 STREET, KESARIANI J3 16122